tiprankstipranks
Trending News
More News >
Emyria Ltd (AU:EMD)
ASX:EMD
Australian Market

Emyria Ltd (EMD) AI Stock Analysis

Compare
13 Followers

Top Page

AU

Emyria Ltd

(Sydney:EMD)

Rating:40Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Emyria Ltd's stock is primarily hindered by its poor financial performance and valuation metrics. The technical analysis suggests potential, yet weak, support due to oversold conditions. The absence of positive earnings call data or significant corporate events further limits the score.

Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)

Emyria Ltd Business Overview & Revenue Model

Company DescriptionEmyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops cannabinoid-based medicines, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and irritable bowel syndrome; and EMD-RX7 for multiple medical conditions. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
How the Company Makes MoneyEmyria Ltd generates revenue primarily through its drug development and clinical trial services. The company's revenue streams include partnerships with pharmaceutical companies for the co-development of new therapies, which often involve milestone payments and royalties from successful commercialization. Emyria also earns income from conducting clinical trials and offering data analytics services to healthcare providers and research institutions. Significant partnerships with leading pharmaceutical firms and research organizations contribute to Emyria's earnings by providing funding and collaborative opportunities in drug development and clinical research.

Emyria Ltd Financial Statement Overview

Summary
Emyria Ltd faces significant challenges in profitability and cash flow stability. While there is some revenue growth, it is overshadowed by operational inefficiencies and high leverage. The financial position indicates potential risks in sustaining operations without strategic improvements or external financing.
Income Statement
35
Negative
Emyria Ltd shows a declining trend in revenue with significant negative gross and net profit margins. The revenue growth rate between 2023 and 2024 is 38.34%, but profitability indicators like EBIT and EBITDA margins are negative, indicating operational challenges.
Balance Sheet
40
Negative
The company has a high debt-to-equity ratio, indicating potential leverage risks. Equity is shrinking, reflecting a decrease in financial stability. Return on Equity (ROE) is negative due to net losses, while the equity ratio is relatively low, suggesting high liabilities compared to assets.
Cash Flow
45
Neutral
Emyria Ltd's cash flow statements show negative operating and free cash flows, although there is some improvement in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow difficulties. Financing activities are helping to offset cash flow issues, but sustainability is a concern.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
1.77M2.20M1.59M1.82M1.98M1.01M
Gross Profit
-172.42K-167.55K-3.32M-4.41M-1.58M-2.79M
EBIT
-2.75M-6.90M-7.12M-8.54M-5.71M-5.63M
EBITDA
-399.76K-13.03M-4.14M-6.74M-4.49M-4.80M
Net Income Common Stockholders
-1.63M-11.46M-5.13M-7.33M-4.91M-5.24M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.55M1.57M2.73M3.88M6.53M3.69M
Total Assets
5.04M5.43M10.16M8.25M9.06M5.06M
Total Debt
802.68K1.72M1.27M632.70K949.70K610.82K
Net Debt
-748.38K152.47K-1.46M-3.25M-5.58M-3.08M
Total Liabilities
1.63M3.00M3.37M1.93M1.88M1.28M
Stockholders Equity
3.41M2.43M6.79M6.32M7.18M3.78M
Cash FlowFree Cash Flow
-973.65K-4.44M-7.01M-7.46M-4.60M-4.65M
Operating Cash Flow
-812.51K-4.28M-3.77M-5.43M-3.94M-4.45M
Investing Cash Flow
-1.18M-1.38M-3.23M-2.03M-661.39K-201.81K
Financing Cash Flow
1.58M4.50M5.86M4.81M7.44M5.73M

Emyria Ltd Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.03
Price Trends
50DMA
0.03
Negative
100DMA
0.03
Negative
200DMA
0.03
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
50.63
Neutral
STOCH
-8.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EMD, the sentiment is Neutral. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.63 is Neutral, neither overbought nor oversold. The STOCH value of -8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:EMD.

Emyria Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
AUEMD
40
Neutral
AU$12.77M-74.80%-9.16%89.23%
$2.16M-119.28%
$25.01M-75.39%
AURAC
54
Neutral
AU$205.88M-37.20%32.02%
AUIDT
44
Neutral
AU$41.35M-19.31%72.25%43.66%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:EMD
Emyria Ltd
0.03
-0.02
-40.00%
BITRF
Biotron Limited
0.05
0.01
25.00%
CYYNF
Cynata Therapeutics Limited
0.12
<0.01
9.09%
AU:RAC
Race Oncology Ltd.
1.18
-0.72
-37.89%
AU:IDT
IDT Australia Limited
0.10
-0.02
-16.67%

Emyria Ltd Corporate Events

Emyria Reports Promising Six-Month PTSD Treatment Outcomes
May 27, 2025

Emyria Limited has announced promising six-month follow-up results from its treatment program for patients with treatment-resistant PTSD, showing significant symptom improvement and quality-of-life gains. The results highlight the effectiveness of Emyria’s structured, psychiatrist-led care model, which has shown to provide meaningful and sustained improvements in a real-world setting, positioning the company as a global leader in PTSD treatment.

David Pevcic Ceases Substantial Holding in Emyria Ltd
May 19, 2025

Emyria Ltd has announced that David Dominic Pevcic has ceased to be a substantial holder in the company as of March 31, 2025. This change is due to the dilution of shares resulting from a placement, affecting over 20 million voting securities. The announcement reflects a shift in the company’s shareholder structure, which may influence its governance and strategic direction.

Emyria Reports Positive Outcomes and Strategic Expansion
Apr 29, 2025

Emyria Limited reported significant clinical outcomes from its PTSD treatment program, with patients showing substantial improvements in symptoms and quality of life. The company also launched a treatment-resistant depression program, engaged with health funders for pilot programs, restructured its leadership, and expanded its treatment capacity by opening a new Empax Centre.

Emyria Expands Mental Health Services with New Empax Centre
Apr 13, 2025

Emyria Limited has opened its second Empax Centre within Perth Clinic, a leading private mental health hospital in Western Australia, expanding its treatment capacity by 50%. This move is part of a broader strategy to meet growing national demand and align with healthcare funders’ requirements for evidence-based mental health therapies. The new centre will initially treat patients with PTSD and treatment-resistant depression, with plans for further expansion on the East Coast. The initiative reflects Emyria’s commitment to scalable, evidence-based care and its potential for lasting patient impact, supported by private insurers and major payers.

Emyria Limited Issues New Shares for Immediate Trading
Mar 31, 2025

Emyria Limited has announced the issuance of 28,571,429 new fully paid ordinary shares at an issue price of $0.035 per share. This move allows the shares to be traded immediately under the exemption provided by section 708A(5) of the Corporations Act, indicating compliance with relevant legal provisions and enabling enhanced liquidity for stakeholders.

Emyria Limited Updates Director’s Interest with Strategic Share Acquisition
Mar 31, 2025

Emyria Limited announced a change in the director’s interest, specifically for Mr. Greg Hutchinson. The update includes the acquisition of 28,571,429 fully paid ordinary shares, 2,500,000 performance rights, and 5,000,000 unlisted options as part of a placement to raise $1 million and under the Company’s Employee Securities Incentive Plan. This change reflects Emyria’s strategic move to strengthen its financial position and incentivize its leadership, potentially impacting its market dynamics and stakeholder confidence.

Emyria Ltd Issues Unquoted Equity Securities for Employee Incentive
Mar 31, 2025

Emyria Ltd has announced the issuance of unquoted equity securities, including 2.5 million performance rights and 7 million options exercisable at $0.051 each, expiring in March 2028. This move is part of an employee incentive scheme and is not intended for public trading on the ASX, potentially enhancing employee engagement and aligning interests with company performance.

Emyria Ltd Announces Quotation of New Securities on ASX
Mar 31, 2025

Emyria Ltd has announced the quotation of 28,571,429 fully paid ordinary shares on the Australian Securities Exchange (ASX), effective March 28, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning and providing new opportunities for stakeholders.

Emyria Ltd Successfully Passes All Resolutions at Shareholder Meeting
Mar 19, 2025

Emyria Ltd announced that all resolutions presented at its General Meeting of Shareholders were successfully passed by a poll. This outcome reflects strong shareholder support for the company’s strategic decisions, including the ratification and approval of various share and option issuances. The resolutions are expected to enhance Emyria’s operational capabilities and align management incentives with shareholder interests, potentially strengthening its market position.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.